CompletedNCT01086748

A Comparator Study of LY2140023 Versus Placebo in Schizophrenia Patients

Researchers compared LY2140023, Risperidone and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.

Medication studyAges 18–65Multiple countries

The study in practice

Understand this study

Researchers compared LY2140023, Risperidone and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations: Escondido and 27 more locationsSee all locations and recruitment
Study phase: Phase 2

Study clarity

Study start dateMarch 2010

Recruitment status: Completed
Enrollment listed in the registry: 1,134
Sponsor: Denovo Biopharma LLC
Sponsor type: Biotech company
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 2
Locations: United States, Croatia, Russia
Age range: From 18 Years to 65 Years
Official registry ID: NCT01086748
Official title: Show the full official title
A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia

Completed

Escondido, United States · Garden Grove, United States · Paramount, United States

26 more locations

FAQ

What did researchers investigate?

Researchers compared LY2140023, Risperidone and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.

Who is behind this study?

The study sponsor is Denovo Biopharma LLC.

Did this study involve medication?

Yes. The study involved medication, including Risperidone, Placebo and LY2140023.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.